Remote management of anaemia in patients with end-stage kidney disease using a wearable, non-invasive sensor.

Anaemia is a prevalent complication in patients with end-stage kidney disease (ESKD) undergoing haemodialysis. This study evaluates the accuracy of the Alio SmartPatch™, a non-invasive remote monitoring device, in measuring haemoglobin (Hb) and haematocrit (Hct) levels in haemodialysis patients by comparing its results with standard blood-based laboratory methods. The results from 116 patients across multiple sites in the USA and the Kingdom of Jordan show that SmartPatch measurements align closely with standard blood-based laboratory methods, meeting clinically acceptable limits of agreement. The current standard methods of Hb and Hct measurements are invasive and require visits to clinical sites, whereas the FDA-cleared SmartPatch offers non-invasive measurement of these parameters up to 240 times per month, thereby enhancing personalized care and patient engagement. This study demonstrates the potential of remote monitoring technologies, such as the SmartPatch, to improve the management of ESKD-associated anaemia. Further research is warranted to evaluate the device's long-term outcomes and its impact across diverse patient populations.